Q2-osavuosiraportti
63 päivää sitten‧40 min
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
78
Myynti
Määrä
8 887
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 000 | NON | AVA | ||
| 4 617 | NON | AVA | ||
| 2 000 | NON | AVA | ||
| 150 | NON | AVA | ||
| 1 000 | NON | AVA |
Ylin
4,88VWAP
Alin
4,39VaihtoMäärä
0,2 41 812
VWAP
Ylin
4,88Alin
4,39VaihtoMäärä
0,2 41 812
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Danske Bank A/S | 14 229 | 0 | +14 229 | 0 |
| Nordnet Bank AB | 30 171 | 19 360 | +10 811 | 10 859 |
| SSW Market Making GmbH | 6 378 | 6 378 | 0 | 0 |
| Avanza Bank AB | 2 422 | 27 462 | −25 040 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Avanza Bank AB | 2 422 | 27 462 | −25 040 | 0 |
| SSW Market Making GmbH | 6 378 | 6 378 | 0 | 0 |
| Nordnet Bank AB | 30 171 | 19 360 | +10 811 | 10 859 |
| Danske Bank A/S | 14 229 | 0 | +14 229 | 0 |
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 27.11. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 28.8. | |
| 2024 Yhtiökokous | 28.5. | |
| Merkintäoikeusanti | 30.4. | |
| 2025 Q1-osavuosiraportti | 25.4. | |
| 2025 Ylimääräinen yhtiökokous | 23.4. |
Datan lähde: Millistream, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
23 t sitten·I think it's positive news, but ok, it's the start of an experiment, not a result, so maybe that's why the stock is so quiet and even sinking a bit?
1 päivä sitten · Muokattu1 päivä sitten · MuokattuNydelig start på dagen med denne børsmeldinge. Curasight advances Phase 2 uTRACE prostate cancer trial with all European clinical sites in Part 2 now recruiting Part 1 of the trial is completed Part 2 recruitment well underway; completion expected in the first half of 2026 The Phase 2 study in prostate cancer is part of the agreement between Curium Inc. and Curasight signed in May 2023 Og les dette: "We are very pleased with the progress of the uTRACE program in prostate cancer," said Curasight CEO Ulrich Krasilnikoff. "Part 1 supported the feasibility of our imaging approach and with all clinical sites now activated in the second part of the trial, we expect to recruitment completed in the first half of 2026". As well as the Phase 2 study in prostate cancer, Curasight anticipates launching a Phase 1 trial testing its therapeutic platform uTREAT® in brain cancer during the current quarter. https://www.nordnet.no/market/news/05cd3a31-7080-4728-8d73-85f8749760c3
1 päivä sitten · Muokattu·H1 2026 is just going to be a wild half-year here. Rarely have I felt so confident that something can go to the moon and beyond within just 9 months. The share still doesn't even cost 5kr... absurd.
1 päivä sitten·Is today's pm from Fluoguide positive for Cura, what is the relationship between these?1 päivä sitten·In some way, it can't be negative - and perhaps it confirms a thesis that Cura could enter a phase where they are a target for acquisition next year on the back of the right data Personally, I have a hard time completely cutting ties between them, as the technology partially overlaps a bit. That is, in my world, a green light for one in some way must at least be a positive indicator for the other. We are of course not talking 1:1, but they should swing together a little bit
20.10.·In my view, nothing has ever slipped. On the contrary, we see a company that has hit on something with far greater potential than they may have initially assumed. It is not a delay, it is a strategic expansion. Curasight / Flouguide and their team have clearly identified new opportunities, both within several types of cancer and treatment methods, and have therefore had to adjust the timeline. Not because something has gone wrong, but because the ambitions have grown. More studies, wider application, larger market. I do not believe that adjustments should be interpreted as weakness. In this case, it is rather a sign that the platform has proven to be more useful than initially assumed. And of course, this requires more studies and tests, which drags on the process and which will ultimately increase the value. Looking forward to hopefully more good results, not least for patients. And so today's price is just a snapshot.20.10.·What is this thing everyone is referring to here? That now here and now has slipped? Delay. Adjust the timeline? Is the process dragging? Fair enough, you are positive overall, but things are going according to plan and there is something new in Q4. It is expected: to enroll the first patient in Q4 and at the same time have the first preliminary efficacy data in Q4, which is what big pharma needs to be able to assess the case. That it falls now is expected and perfect if you want to increase your position towards the next run up, when data arrives in Q4. If you believe even a little in Cura/Fluo and their technology, then you buy Cura with arms and legs now. Especially if you didn't have time to act big when it bottomed out around 2. However, there are still many who feel burned by the case and therefore it will take a little more than usual for confidence to return. But still. Now it's trading at 4.5, maybe it'll go lower. And there's data coming soon. No recommendation, but...20.10.·I don't agree. When the price hit 6.5, it was a peak that was visible. And that it would then cool down and gather momentum until Q4 and the next run. Now it has established itself fairly solidly in the 4.5-5.5 range over a longer period of time and the time when new information is announced is just getting closer. There is no turnover, exactly, so I don't understand all this about people writing about things that are delayed, postponed, etc. If I had written things down in the summer of 2025, it would not only have gone according to plan - but you should be ahead of schedule. The price has also done exactly what you expect - and now it's just a bow that is stretched forward towards the next call for data. Of course, you can think that they are wrong - and then you should keep your fingers away. Or you can think that they have some technology that is really moving and that good data is landing on it. I'm currently increasing my position, I think it's getting too cheap now, even though it means my GAK is moving closer to 2.5 than the 2. Disclaimer, I have a fairly large position in the company, so I'm naturally biased up over my ears.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Q2-osavuosiraportti
63 päivää sitten‧40 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 23 t sitten·I think it's positive news, but ok, it's the start of an experiment, not a result, so maybe that's why the stock is so quiet and even sinking a bit?
- 1 päivä sitten · Muokattu1 päivä sitten · MuokattuNydelig start på dagen med denne børsmeldinge. Curasight advances Phase 2 uTRACE prostate cancer trial with all European clinical sites in Part 2 now recruiting Part 1 of the trial is completed Part 2 recruitment well underway; completion expected in the first half of 2026 The Phase 2 study in prostate cancer is part of the agreement between Curium Inc. and Curasight signed in May 2023 Og les dette: "We are very pleased with the progress of the uTRACE program in prostate cancer," said Curasight CEO Ulrich Krasilnikoff. "Part 1 supported the feasibility of our imaging approach and with all clinical sites now activated in the second part of the trial, we expect to recruitment completed in the first half of 2026". As well as the Phase 2 study in prostate cancer, Curasight anticipates launching a Phase 1 trial testing its therapeutic platform uTREAT® in brain cancer during the current quarter. https://www.nordnet.no/market/news/05cd3a31-7080-4728-8d73-85f8749760c31 päivä sitten · Muokattu·H1 2026 is just going to be a wild half-year here. Rarely have I felt so confident that something can go to the moon and beyond within just 9 months. The share still doesn't even cost 5kr... absurd.
- 1 päivä sitten·Is today's pm from Fluoguide positive for Cura, what is the relationship between these?1 päivä sitten·In some way, it can't be negative - and perhaps it confirms a thesis that Cura could enter a phase where they are a target for acquisition next year on the back of the right data Personally, I have a hard time completely cutting ties between them, as the technology partially overlaps a bit. That is, in my world, a green light for one in some way must at least be a positive indicator for the other. We are of course not talking 1:1, but they should swing together a little bit
- 20.10.·In my view, nothing has ever slipped. On the contrary, we see a company that has hit on something with far greater potential than they may have initially assumed. It is not a delay, it is a strategic expansion. Curasight / Flouguide and their team have clearly identified new opportunities, both within several types of cancer and treatment methods, and have therefore had to adjust the timeline. Not because something has gone wrong, but because the ambitions have grown. More studies, wider application, larger market. I do not believe that adjustments should be interpreted as weakness. In this case, it is rather a sign that the platform has proven to be more useful than initially assumed. And of course, this requires more studies and tests, which drags on the process and which will ultimately increase the value. Looking forward to hopefully more good results, not least for patients. And so today's price is just a snapshot.20.10.·What is this thing everyone is referring to here? That now here and now has slipped? Delay. Adjust the timeline? Is the process dragging? Fair enough, you are positive overall, but things are going according to plan and there is something new in Q4. It is expected: to enroll the first patient in Q4 and at the same time have the first preliminary efficacy data in Q4, which is what big pharma needs to be able to assess the case. That it falls now is expected and perfect if you want to increase your position towards the next run up, when data arrives in Q4. If you believe even a little in Cura/Fluo and their technology, then you buy Cura with arms and legs now. Especially if you didn't have time to act big when it bottomed out around 2. However, there are still many who feel burned by the case and therefore it will take a little more than usual for confidence to return. But still. Now it's trading at 4.5, maybe it'll go lower. And there's data coming soon. No recommendation, but...20.10.·I don't agree. When the price hit 6.5, it was a peak that was visible. And that it would then cool down and gather momentum until Q4 and the next run. Now it has established itself fairly solidly in the 4.5-5.5 range over a longer period of time and the time when new information is announced is just getting closer. There is no turnover, exactly, so I don't understand all this about people writing about things that are delayed, postponed, etc. If I had written things down in the summer of 2025, it would not only have gone according to plan - but you should be ahead of schedule. The price has also done exactly what you expect - and now it's just a bow that is stretched forward towards the next call for data. Of course, you can think that they are wrong - and then you should keep your fingers away. Or you can think that they have some technology that is really moving and that good data is landing on it. I'm currently increasing my position, I think it's getting too cheap now, even though it means my GAK is moving closer to 2.5 than the 2. Disclaimer, I have a fairly large position in the company, so I'm naturally biased up over my ears.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
78
Myynti
Määrä
8 887
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 000 | NON | AVA | ||
| 4 617 | NON | AVA | ||
| 2 000 | NON | AVA | ||
| 150 | NON | AVA | ||
| 1 000 | NON | AVA |
Ylin
4,88VWAP
Alin
4,39VaihtoMäärä
0,2 41 812
VWAP
Ylin
4,88Alin
4,39VaihtoMäärä
0,2 41 812
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Danske Bank A/S | 14 229 | 0 | +14 229 | 0 |
| Nordnet Bank AB | 30 171 | 19 360 | +10 811 | 10 859 |
| SSW Market Making GmbH | 6 378 | 6 378 | 0 | 0 |
| Avanza Bank AB | 2 422 | 27 462 | −25 040 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Avanza Bank AB | 2 422 | 27 462 | −25 040 | 0 |
| SSW Market Making GmbH | 6 378 | 6 378 | 0 | 0 |
| Nordnet Bank AB | 30 171 | 19 360 | +10 811 | 10 859 |
| Danske Bank A/S | 14 229 | 0 | +14 229 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 27.11. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 28.8. | |
| 2024 Yhtiökokous | 28.5. | |
| Merkintäoikeusanti | 30.4. | |
| 2025 Q1-osavuosiraportti | 25.4. | |
| 2025 Ylimääräinen yhtiökokous | 23.4. |
Datan lähde: Millistream, Quartr
Q2-osavuosiraportti
63 päivää sitten‧40 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 27.11. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 28.8. | |
| 2024 Yhtiökokous | 28.5. | |
| Merkintäoikeusanti | 30.4. | |
| 2025 Q1-osavuosiraportti | 25.4. | |
| 2025 Ylimääräinen yhtiökokous | 23.4. |
Datan lähde: Millistream, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 23 t sitten·I think it's positive news, but ok, it's the start of an experiment, not a result, so maybe that's why the stock is so quiet and even sinking a bit?
- 1 päivä sitten · Muokattu1 päivä sitten · MuokattuNydelig start på dagen med denne børsmeldinge. Curasight advances Phase 2 uTRACE prostate cancer trial with all European clinical sites in Part 2 now recruiting Part 1 of the trial is completed Part 2 recruitment well underway; completion expected in the first half of 2026 The Phase 2 study in prostate cancer is part of the agreement between Curium Inc. and Curasight signed in May 2023 Og les dette: "We are very pleased with the progress of the uTRACE program in prostate cancer," said Curasight CEO Ulrich Krasilnikoff. "Part 1 supported the feasibility of our imaging approach and with all clinical sites now activated in the second part of the trial, we expect to recruitment completed in the first half of 2026". As well as the Phase 2 study in prostate cancer, Curasight anticipates launching a Phase 1 trial testing its therapeutic platform uTREAT® in brain cancer during the current quarter. https://www.nordnet.no/market/news/05cd3a31-7080-4728-8d73-85f8749760c31 päivä sitten · Muokattu·H1 2026 is just going to be a wild half-year here. Rarely have I felt so confident that something can go to the moon and beyond within just 9 months. The share still doesn't even cost 5kr... absurd.
- 1 päivä sitten·Is today's pm from Fluoguide positive for Cura, what is the relationship between these?1 päivä sitten·In some way, it can't be negative - and perhaps it confirms a thesis that Cura could enter a phase where they are a target for acquisition next year on the back of the right data Personally, I have a hard time completely cutting ties between them, as the technology partially overlaps a bit. That is, in my world, a green light for one in some way must at least be a positive indicator for the other. We are of course not talking 1:1, but they should swing together a little bit
- 20.10.·In my view, nothing has ever slipped. On the contrary, we see a company that has hit on something with far greater potential than they may have initially assumed. It is not a delay, it is a strategic expansion. Curasight / Flouguide and their team have clearly identified new opportunities, both within several types of cancer and treatment methods, and have therefore had to adjust the timeline. Not because something has gone wrong, but because the ambitions have grown. More studies, wider application, larger market. I do not believe that adjustments should be interpreted as weakness. In this case, it is rather a sign that the platform has proven to be more useful than initially assumed. And of course, this requires more studies and tests, which drags on the process and which will ultimately increase the value. Looking forward to hopefully more good results, not least for patients. And so today's price is just a snapshot.20.10.·What is this thing everyone is referring to here? That now here and now has slipped? Delay. Adjust the timeline? Is the process dragging? Fair enough, you are positive overall, but things are going according to plan and there is something new in Q4. It is expected: to enroll the first patient in Q4 and at the same time have the first preliminary efficacy data in Q4, which is what big pharma needs to be able to assess the case. That it falls now is expected and perfect if you want to increase your position towards the next run up, when data arrives in Q4. If you believe even a little in Cura/Fluo and their technology, then you buy Cura with arms and legs now. Especially if you didn't have time to act big when it bottomed out around 2. However, there are still many who feel burned by the case and therefore it will take a little more than usual for confidence to return. But still. Now it's trading at 4.5, maybe it'll go lower. And there's data coming soon. No recommendation, but...20.10.·I don't agree. When the price hit 6.5, it was a peak that was visible. And that it would then cool down and gather momentum until Q4 and the next run. Now it has established itself fairly solidly in the 4.5-5.5 range over a longer period of time and the time when new information is announced is just getting closer. There is no turnover, exactly, so I don't understand all this about people writing about things that are delayed, postponed, etc. If I had written things down in the summer of 2025, it would not only have gone according to plan - but you should be ahead of schedule. The price has also done exactly what you expect - and now it's just a bow that is stretched forward towards the next call for data. Of course, you can think that they are wrong - and then you should keep your fingers away. Or you can think that they have some technology that is really moving and that good data is landing on it. I'm currently increasing my position, I think it's getting too cheap now, even though it means my GAK is moving closer to 2.5 than the 2. Disclaimer, I have a fairly large position in the company, so I'm naturally biased up over my ears.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
78
Myynti
Määrä
8 887
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 000 | NON | AVA | ||
| 4 617 | NON | AVA | ||
| 2 000 | NON | AVA | ||
| 150 | NON | AVA | ||
| 1 000 | NON | AVA |
Ylin
4,88VWAP
Alin
4,39VaihtoMäärä
0,2 41 812
VWAP
Ylin
4,88Alin
4,39VaihtoMäärä
0,2 41 812
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Danske Bank A/S | 14 229 | 0 | +14 229 | 0 |
| Nordnet Bank AB | 30 171 | 19 360 | +10 811 | 10 859 |
| SSW Market Making GmbH | 6 378 | 6 378 | 0 | 0 |
| Avanza Bank AB | 2 422 | 27 462 | −25 040 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Avanza Bank AB | 2 422 | 27 462 | −25 040 | 0 |
| SSW Market Making GmbH | 6 378 | 6 378 | 0 | 0 |
| Nordnet Bank AB | 30 171 | 19 360 | +10 811 | 10 859 |
| Danske Bank A/S | 14 229 | 0 | +14 229 | 0 |